Standard of Care: Treating the Cause and Lowering the Counts
At a Glance
Treatment for hypereosinophilia depends on the cause and organ involvement. Steroids often act first; imatinib targets certain gene changes, while biologics or other immune medicines may reduce relapses and long-term steroid exposure.
Treatment for hypereosinophilia (HE) is not a “one size fits all” approach. Because eosinophils can damage the heart and other organs rapidly, your medical team must move quickly to identify the underlying cause and start the right therapy [1][2].
The primary goal of treatment is to prevent or reverse organ damage and control the underlying disease. While a common laboratory reference target is an absolute eosinophil count (AEC) below 500/µL, a normal AEC does not necessarily establish remission or exclude ongoing disease activity [1].
Safety Warning: Do not start, stop, or alter your steroids, anticoagulants, or immune medications without explicit guidance from your care team.
First-Line Therapy: Glucocorticoids
For most patients with idiopathic HES or EGPA, glucocorticoids (often called corticosteroids or “steroids,” such as prednisone) are the first line of defense [3].
- The Goal: Steroids work quickly to suppress the immune system and lower the number of eosinophils in your blood [4].
- Emergency Use: If you have active life-threatening organ damage, such as heart inflammation, your doctor may start high-dose intravenous “pulse” steroids immediately, sometimes even before a final diagnosis is confirmed [5][6].
- Strongyloides Warning: If you have a relevant travel or residence history, your doctor must assess for Strongyloides (a parasite). High-dose steroids can precipitate a fatal hyperinfection. If testing cannot wait, clinicians may provide empiric antiparasitic treatment alongside urgent steroids.
Targeted Therapy for Genetic Causes
If your diagnostic workup reveals a specific genetic mutation, such as a PDGFRA or PDGFRB fusion, your treatment will shift to targeted therapy.
- Imatinib: This is a pill taken daily. For patients with the FIP1L1-PDGFRA mutation or certain PDGFRB fusions, imatinib is highly effective, often leading to complete remission at very low doses [7][8][9]. FGFR1 and PCM1-JAK2 rearrangements require different specialist-directed strategies.
- Long-Term Monitoring: Because these fusions are a “primary” bone marrow issue, patients often stay on targeted therapy long-term, with regular molecular testing to ensure the mutation remains suppressed [8].
Advanced Treatment for EGPA
For EGPA (Eosinophilic Granulomatosis with Polyangiitis), treatment depends on whether the disease is “severe” (meaning it threatens your life or an organ) or “non-severe.”
Severe EGPA
When EGPA affects the heart, kidneys, or nerves (vasculitis), more intensive “induction” therapy is needed to achieve remission [10].
- Cyclophosphamide: A potent immunosuppressant often used alongside high-dose steroids for severe cases [11][12].
- Rituximab: An alternative to cyclophosphamide that targets specific immune cells (B cells). Current guidelines support that both may be considered in selected patients, with the choice depending on organ involvement, ANCA status, fertility, and infection risks [13][14].
Non-Severe or Relapsing EGPA
If the disease is less aggressive or keeps coming back, doctors often use “steroid-sparing” agents.
- Mepolizumab: This is a biologic that blocks IL-5, the main “fuel” for eosinophils [15]. In trials, patients taking mepolizumab had significantly more weeks in remission and were able to lower their steroid doses compared to those taking a placebo [16].
- Benralizumab: A newer biologic that works similarly to mepolizumab. Recent studies show it has demonstrated efficacy in achieving remission and may be considered in selected patients depending on local availability and clinical history [17].
Treatment for Idiopathic HES
When no genetic mutation or vasculitis is found (idiopathic HES), the focus is on finding a maintenance therapy that keeps eosinophils low without the long-term side effects of steroids.
- Mepolizumab for HES: Similar to its use in EGPA, mepolizumab is approved for HES. In a 32-week clinical trial (study 200622), it reduced the number of “flares” (worsening symptoms) by 50% [18][19].
- Other Options: If steroids and biologics are not enough, doctors may use medications like hydroxyurea, interferon-alpha, or azathioprine to help maintain low counts [9][20].
Treatment Checklist
Because these medications are powerful, your doctor will monitor you closely for side effects and safety:
- Infection Risk: Steroids and immunosuppressants can make it harder to fight infections. Depending on the drug and urgency, your doctor should check your Hepatitis B and tuberculosis status, and update your vaccinations before you start [21].
- Cardiac Support: If you have heart involvement, you may also need standard heart failure medications, such as beta-blockers or ACE inhibitors, alongside your eosinophil-suppressing therapy [1][22].
- Bone Health: Long-term steroid use can weaken bones, so you may need calcium, vitamin D, or bone-strengthening medications.
- Anticoagulation: If you have had a blood clot, you will receive individualized anticoagulation. The duration depends on the clot type, recurrence risk, cardiac thrombus, and bleeding risk; a normal eosinophil count does not by itself authorize stopping therapy [23][24].
Common questions in this guide
What is usually used first to treat hypereosinophilia?
When can imatinib help with a high eosinophil count?
How is severe EGPA treated?
What medicines can reduce the need for long-term steroids?
Why should Strongyloides be checked before high-dose steroids?
Does a normal eosinophil count mean treatment can stop?
Get notified when new evidence is published on platelet abnormalities with eosinophilia and immune-mediated inflammatory disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (24)
- 1
The portrait of a stranger: the hypereosinophilic syndrome with cardiac involvement.
Ivănescu AC, Petre A, Marincaș AS, et al.
Romanian journal of internal medicine = Revue roumaine de medecine interne 2023; (61(4)):222-227 doi:10.2478/rjim-2023-0016.
PMID: 37493620 - 2
HES and EGPA: Two Sides of the Same Coin.
Khoury P, Akuthota P, Kwon N, et al.
Mayo Clinic proceedings 2023; (98(7)):1054-1070 doi:10.1016/j.mayocp.2023.02.013.
PMID: 37419574 - 3
Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.
Kim DH, Kim S, Park S, et al.
British journal of haematology 2024; (205(6)):2305-2314 doi:10.1111/bjh.19828.
PMID: 39389908 - 4
Eosinophilic myocarditis: case series and literature review.
Sohn KH, Song WJ, Kim BK, et al.
Asia Pacific allergy 2015; (5(2)):123-7 doi:10.5415/apallergy.2015.5.2.123.
PMID: 25938077 - 5
Fulminant Idiopathic Hypereosinophilic Syndrome Presenting with Cardiac, Neurologic and Haematologic Involvement.
Ibrahim N, Batri A, Rivera RR, Zwein A
European journal of case reports in internal medicine 2025; (12(12)):006010 doi:10.12890/2025_006010.
PMID: 41536447 - 6
Eosinophilic myocarditis: systematic review.
Techasatian W, Gozun M, Vo K, et al.
Heart (British Cardiac Society) 2024; (110(10)):687-693 doi:10.1136/heartjnl-2023-323225.
PMID: 37963727 - 7
Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert review of clinical immunology 2018; (14(2)):163-170 doi:10.1080/1744666X.2018.1425142.
PMID: 29303368 - 8
Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
Khoury P, Desmond R, Pabon A, et al.
Allergy 2016; (71(6)):803-10 doi:10.1111/all.12843.
PMID: 26797802 - 9
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
American journal of hematology 2022; (97(1)):129-148 doi:10.1002/ajh.26352.
PMID: 34533850 - 10
[Eosinophilic granulomatosis with polyangiitis: a review article].
Schindler V, Venhoff N
Laryngo- rhino- otologie 2024; (103(10)):705-714 doi:10.1055/a-2214-1669.
PMID: 38964344 - 11
[Multidisciplinary expert consensus on diagnosis and treatment of eosinophilic granulomatosis with polyangiitis (2025 Edition)].
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2025; (48(5)):418-439 doi:10.3760/cma.j.cn112147-20250110-00027.
PMID: 40300867 - 12
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.
Annals of the rheumatic diseases 2024; (83(1)):30-47 doi:10.1136/ard-2022-223764.
PMID: 36927642 - 13
Updated treatment approaches for eosinophilic granulomatosis with polyangiitis: A systematic scoping review.
Shiomi M, Higuchi T, Akiyama M, et al.
Modern rheumatology 2026; (36(3)):415-421 doi:10.1093/mr/roaf126.
PMID: 41427848 - 14
Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J, Troilo A, Salzer U, et al.
The journal of allergy and clinical immunology. In practice 2017; (5(6)):1556-1563 doi:10.1016/j.jaip.2017.07.027.
PMID: 28916432 - 15
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Chung SA, Langford CA, Maz M, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(8)):1366-1383 doi:10.1002/art.41773.
PMID: 34235894 - 16
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Akuthota P, Jayne D, et al.
The New England journal of medicine 2017; (376(20)):1921-1932 doi:10.1056/NEJMoa1702079.
PMID: 28514601 - 17
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, et al.
The New England journal of medicine 2024; (390(10)):911-921 doi:10.1056/NEJMoa2311155.
PMID: 38393328 - 18
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Roufosse F, Kahn JE, Rothenberg ME, et al.
The Journal of allergy and clinical immunology 2020; (146(6)):1397-1405 doi:10.1016/j.jaci.2020.08.037.
PMID: 32956756 - 19
Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
Reiter A, Lefevre G, Cid MC, et al.
Frontiers in immunology 2022; (13()):840974 doi:10.3389/fimmu.2022.840974.
PMID: 35493455 - 20
Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome.
Holle JU, Vaglio A
Rheumatology (Oxford, England) 2025; (64(12 Suppl 2)):i92-i97 doi:10.1093/rheumatology/keae608.
PMID: 40071429 - 21
Literature review and case study of recurrent EPGA with elevated IgG4 and positive HBsAg successfully treated with rituximab.
Wang J, Wang J, Wang N, et al.
Renal failure 2024; (46(2)):2390569 doi:10.1080/0886022X.2024.2390569.
PMID: 39169678 - 22
Eosinophilic myocarditis and hypereosinophilic syndrome.
Boussir H, Ghalem A, Ismaili N, El Ouafi N
Journal of the Saudi Heart Association 2017; (29(3)):211-213 doi:10.1016/j.jsha.2016.11.001.
PMID: 28652675 - 23
[Ten questions about eosinophilic myocarditis].
Pagura L, Imazio M, Merlo M, Sinagra G
Giornale italiano di cardiologia (2006) 2022; (23(4)):259-267 doi:10.1714/3766.37535.
PMID: 35343477 - 24
FIP1L1-PDGFRA Clonal Hypereosinophilic Syndrome With Eosinophilic Myocarditis and Intracardiac Thrombus.
Locke M, Suen RM, Williamson AK, Nieto MJ
Cureus 2023; (15(8)):e43138 doi:10.7759/cureus.43138.
PMID: 37692703
This page explains treatment approaches for hypereosinophilia, HES, and EGPA for educational purposes only and does not replace medical advice. Do not change steroids, anticoagulants, or immune medicines without guidance from your treating team.